# Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

> **NCT07734038** · PHASE2 · RECRUITING · sponsor: **Kerry Rogers** · enrollment: 155 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Venetoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT07734038
- **Lead sponsor:** Kerry Rogers
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2026-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734038, "Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*